119
Participants
Start Date
December 31, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
February 28, 2014
abatacept
solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
Methotrexate (MTX)
Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Local Institution, Malvern
Local Institution, Berea
Local Institution, Maroochydore
Local Institution, Hobart
Local Institution, Panorama
Regional Rheumatology Associates, Binghamton
Altoona Center For Clinical Research, Duncansville
East Penn Rheumatology Associates, Bethlehem
Physicians East, Pa, Greenville
Columbia Arthritis Center, Columbia
Low Country Rheumatology, Pa, Charleston
The Arthritis Center, Palm Harbor
Rheumatology Associates Of North Alabama, Huntsville
Coastal Clinical Research Inc, Mobile
Medical Towers South, Louisville
Local Institution, Guadalajara
Rheumatic Disease Center, Glendale
Westroads Medical Group, Omaha
Healthcare Research Consultants, Tulsa
Boulder Medical Center, Boulder
Stanford University School Of Medicine, Palo Alto
Local Institution, D.f.
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY